Regeneron Pharmaceuticals will release its second-quarter earnings next month, and analysts anticipate a double-digit profit ...

REGN Quantitative Stock Analysis - Benjamin Graham November 12, 2024 — 10:00 am EST Written by John Reese for Validea -> ...

Regeneron (NASDAQ:REGN) Pharmaceuticals, a leading biotechnology company with a market capitalization of $71.75 billion, has been navigating a complex landscape of opportunities and challenges in ...

The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Regeneron? Access our full analysis report here, it’s free.

Analysts have recently evaluated Regeneron Pharmaceuticals and provided 12-month price targets. The average target is $769.35, accompanied by a high estimate of $975.00 and a low estimate of $547.00.

The volatility in REGN stock is being driven by the developments for REGEN-COV, its Covid-19 antibody cocktail. ... See our analysis on Regeneron Stock Chances of A Rise for more details.

See why I no longer see REGN stock price upside in the near term. Skip to content. ... analysis I set a price target for the stock price of ~$815 - a 10% premium to Regeneron's share price today.

On Thursday, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported third-quarter adjusted EPS of $12.46, up 8% year-over-year, beating the consensus of $11.69. The company reported sales of $3.72 ...

On Tuesday, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported first-quarter adjusted earnings per share of $8.22, down 14% year-over-year, missing the consensus of $8.82. The company reported ...

Of the 22 guru strategies we follow, REGN rates highest using our Value Investor model based on the published strategy of Benjamin Graham. This deep value methodology screens for stocks that hav ...